Cost-effectiveness of the low molecular weight heparin reviparin sodium in thromboprophylaxis.
Use of low molecular weight heparins (LMWHs) is now generally accepted as an ideal method of prophylaxis against postoperative venous thromboembolism. However, the long-term effects on the development of postthrombotic deep vein insufficiency are not known. Every patient developing such complications consumes a vast amount of resources, in terms of both direct and indirect costs. Our cost-effective analysis indicates that LMWH (reviparin sodium) is most cost-saving for both direct and indirect costs, particularly in high risk patients undergoing major surgery.
Kakkar
V V
VV
Thrombosis Research Institute, London, UK.
D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006495:Heparin, Low-Molecular-Weight / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control; D013927:Thrombosis / Q000191:economics / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; C094240:reviparin